U.S. Markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.0235%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.0977%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.3587%)
     
  • BTC-USD

    34,347.73
    +437.64 (+1.29%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

BridgeBio Pharma's BBP-418 Muscular Dystrophy Study Moves Forward With Patient Dosing

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate ML Bio Solutions have dosed the first patient in the Phase 2 trial evaluating BBP-418 in patients with Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i).

  • LGMD2i is an inherited recessive muscular dystrophy caused by mutation of fukutin-related protein (FKRP), leading to chronic muscle injury and loss, muscle weakness, and disability.

  • BBP-418 is designed to bypass the metabolic defect in LGMD2i by providing the FKRP enzyme with precursor sugar molecules that supplement the body's natural sugars used by FKRP to glycosylate the αDG protein on muscle cells.

  • The 16-subject trial will assess the safety and key efficacy measurements, including changes in muscle αDG glycosylation levels and changes in functional measures, including a 10-meter walk and North Star for Dysferlinopathy.

  • Price Action: BBIO increased 4.53% at $66.7 in the market trading hours on last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.